Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies

NCT07112287 is registered in ClinicalTrials.gov with Christopher Reilly as lead sponsor.

NCT NCT07112287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07112287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies
Lead sponsor
Christopher Reilly
Phase
Not applicable
Overall status
Recruiting
Start date
November 10, 2025
Completion date
April 1, 2033
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genetic predisposition to disease, myeloid hematological malignancies, myeloid malignancy